The serum was 100 percent successful following a week in more than 7,600 individuals vaccinated, by distributed in The Lancet therapeutic diary and hailed as "to a great degree promising" by World Wellbeing Association (WHO) boss Margaret Chan.
The world was "very nearly a powerful Ebola antibody," the UN's wellbeing office said in an announcement.
"The starting consequences of the study demonstrate that the antibody can adequately contain the further spread of the Ebola infection," said the College of Bern, which added to the exploration.
Despite the fact that empowering, the outcomes are "between time" and the antibody won't turn out to be instantly accessible as a group wide Ebola shield, specialists advised.
Around 28,000 individuals have been contaminated in Guinea, Sierra Leone and Liberia since late 2013, as per the WHO. About half have kicked the bucket, yet there is thought to be a substantial undercount of cases and passings.
Having conveyed an effectively delicate wellbeing segment to its knees, and driving out abundantly required speculation, the flare-up has begun slowing down however is not over.
Seven cases were affirmed the week finishing in July 26 - four in Guinea and three in Sierra Leone - the most reduced week after week all out for over a year.
Yet, even a solitary undetected case can start a flareup - the infection spreads through direct contact with body liquids.
- All the more testing obliged -
One of two driving immunization applicants, VSV-ZEBOV has been produced and tried in a super-speedy 12 months, contrasted with the typical decade or more. Ebola has no authorized cure or treatment.
The trial, supported by medication firm Merck, the WHO and the administrations of Canada, Norway and Guinea, saw 4,123 high-hazard individuals immunized instantly after somebody near to the trial member fell sick with the haemorrhagic fever.
None of the immunized gathering got the infection.
A second, examination gathering of 3,528 individuals got the antibody three weeks after potential presentation. Sixteen of them gotten the infection while unprotected, said the study, yet by day six after immunization, everybody in the second gathering was additionally completely protected.
"Surely, no vaccinee created indications over six days after immunization, independent of whether inoculation was prompt or postponed," said the study paper.
The antibody was sheltered, without any genuine reactions, as indicated by the study.
Not known is to what extent the insurance endures, or the antibody's impact on pregnant ladies and youngsters - high hazard amasses excluded in the trial.
The news was welcomed with hopefulness in the Guinean capital of Conakry, where the organizer of the nation's battle against the infection, Sakoba Keita, communicated his "incomparable fulfillment" in a public interview late Friday.
"We trust that with this revelation, the shame that we have needed to manage and the apprehension of this sickness will end," Keita said, while including that current measures went for keeping the infection would stay set up.
The WHO's illustrative in Guinea, Mohammed Belhocine, exhorted alert, then again.
"Given the peril of this plague, this is only a fractional result. We ought to praise it, yet should not permit our gatekeeper to drop," he said.
- Constraining infection spread -
The Lancet said the Guinea trial would keep social occasion proof of Versus ZEBOV's adequacy and security.
"The antibody is not yet authorized. More information on viability are required before it can be generally sent," said an article in the restorative diary.
And still, after all that, it might be better utilized not to attempt and counteract episodes, but rather to breaking point infection spread once there is a known case, and for ensuring human services specialists - the gathering at most astounding danger.
"The significant issue is the extremely sporadic appearance of Ebola infection in episodes which are flighty as far as where and when they may next show up," Andrew Easton, a virology teacher at the College of Warwick, told AFP.
What's more, the expense of mass immunization to cover all outcomes would be restrictive.
The trial utilized an alleged "ring" methodology - the same used to destroy smallpox in Africa in the 1970s. To begin with to be immunized are individuals who had been in close contact with an Ebola tolerant, then those at a somewhat more backhanded hazard, etc.
"Where rings have been immunized... the transmission has ceased," WHO right hand chief general Marie-Paule Kieny told columnists in Geneva.
"Preceding the immunization there were cases, cases, cases. The immunization arrived, after 10 days no cases."
For one of the trial specialists, Matthias Egger, said the trial demonstrated the viability of the immunization, as well as of the ring method.
"This could at long last be the start of the end of the Ebola pandemic in West Africa furthermore be helpful when fighting this sickness later on," he said. (AFP)